首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   158632篇
  免费   11482篇
  国内免费   643篇
耳鼻咽喉   2021篇
儿科学   3982篇
妇产科学   2968篇
基础医学   22680篇
口腔科学   3966篇
临床医学   15385篇
内科学   33774篇
皮肤病学   2462篇
神经病学   15071篇
特种医学   6549篇
外国民族医学   46篇
外科学   24109篇
综合类   1321篇
一般理论   277篇
预防医学   11412篇
眼科学   3021篇
药学   10389篇
中国医学   301篇
肿瘤学   11023篇
  2023年   921篇
  2022年   1901篇
  2021年   4269篇
  2020年   2440篇
  2019年   3712篇
  2018年   4402篇
  2017年   3116篇
  2016年   3429篇
  2015年   3904篇
  2014年   5246篇
  2013年   7306篇
  2012年   10533篇
  2011年   10738篇
  2010年   6434篇
  2009年   5526篇
  2008年   9101篇
  2007年   8998篇
  2006年   8781篇
  2005年   8560篇
  2004年   8023篇
  2003年   7356篇
  2002年   6942篇
  2001年   2766篇
  2000年   2694篇
  1999年   2656篇
  1998年   1751篇
  1997年   1426篇
  1996年   1208篇
  1995年   1221篇
  1994年   997篇
  1993年   1055篇
  1992年   1809篇
  1991年   1716篇
  1990年   1629篇
  1989年   1604篇
  1988年   1392篇
  1987年   1366篇
  1986年   1333篇
  1985年   1242篇
  1984年   1045篇
  1983年   954篇
  1982年   795篇
  1981年   771篇
  1980年   640篇
  1979年   774篇
  1978年   567篇
  1977年   534篇
  1975年   506篇
  1974年   546篇
  1973年   457篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
Objective: Acute graft-versus-host disease (aGVHD) is a common and life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The extent to which aGVHD increases inpatient costs associated with allo-HSCT has not been thoroughly evaluated. In this analysis, mortality, hospital length of stay (LOS) and costs associated with aGVHD during allo-HSCT admissions are evaluated.

Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge.

Results: Overall, mortality (16.2% vs. 5.3%; p?<?.01), median hospital LOS (42.0 vs. 26.0 days; p?<?.01) and median total costs ($173,144 vs. $98,982; p?<?.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups.

Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT.  相似文献   

63.
64.
65.
ABSTRACT

Take-Away Points:

1. Geriatric palliative care requires integrating the disciplines of hospital medicine and palliative care in pursuit of delivering comprehensive, whole-person care to aging patients with serious illnesses.

2. Older adults have unique palliative care needs compared to the general population, different prevalence and intensity of symptoms, more frequent neuropsychiatric challenges, increased social needs, distinct spiritual, religious, and cultural considerations, and complex medicolegal and ethical issues.

3. Hospital-based palliative care interdisciplinary teams can take many forms and provide high-quality, goal-concordant care to older adults and their families.  相似文献   
66.
67.
68.
69.

Background

We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.

Methods

In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).

Results

After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).

Conclusions

This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy.  相似文献   
70.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号